HERSHEY, Pa. and ROCKVILLE, Md., March 9, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it will be presenting at the BIO-Europe Spring Conference to be held at the Paris Expo, Porte de Versailles on Tuesday, March 10, 2015 at 4:00 PM, Level 0, Room E.
In addition to the company presentation, ITI CEO, William Hearl, Ph.D. will also be participating in an educational session titled "Land of the Rising Sun: Also the land of opportunity for new business development," to be held today, March 9, at 1:50 PM local time.
The company's presentation comes on the heels of its presentation at the 8th Annual European Life Sciences CEO conference in Zurich.
"Presenting at these conferences presents Immunomic Therapeutics with a tremendous opportunity to convene with potential partners and investors, while explaining the incredible potential of our LAMP-vax platform," said Dr. Hearl. "We are particularly gratified to be part of the additional session outlining opportunities in Japan based on our recent licensing partnership with Astellas Pharma to develop our vaccine for Japanese Red Cedar allergy there."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:
- ASP 4070 (Formerly known as JRC-LAMP-Vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
- An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
- ARA-LAMP-Vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
- Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.
For more information about ITI and LAMP Technology, please visit www.immunomix.com.
CONTACT: Jules Abraham JQA Partners, Inc. firstname.lastname@example.org (917) 885-7378 Sia Anagnostou Immunomic Therapeutics, Inc email@example.com http://www.immunomix.com (717) 327-1822Source:Immunomic Therapeutics, Inc.